Mass spectrometry-based antigen discovery for cancer immunotherapy
- 1 August 2016
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 41, 9-17
Abstract
No abstract availableKeywords
Funding Information
- Ludwig Institute for Cancer Research (LICR)
- National Institute of Health (Ro1-CA156695)
- European Research Council (1400206AdG-322875)
- Leenaards Foundation
- Marcus Foundation
This publication has 87 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalGenome Research, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Exploiting the Mutanome for Tumor VaccinationCancer Research, 2012